Curis (CRIS) Receives Media Sentiment Rating of 0.14

News articles about Curis (NASDAQ:CRIS) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm ranks the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Curis earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 45.9583410614047 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

These are some of the news articles that may have impacted Accern’s scoring:

Several equities research analysts have recently commented on CRIS shares. ValuEngine raised shares of Curis from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Zacks Investment Research raised shares of Curis from a “sell” rating to a “hold” rating in a research report on Monday, July 17th. Finally, BidaskClub raised shares of Curis from a “strong sell” rating to a “sell” rating in a research report on Thursday, August 17th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $5.50.

Shares of Curis (NASDAQ:CRIS) opened at 2.02 on Wednesday. Curis has a 52-week low of $1.47 and a 52-week high of $3.72. The company’s market capitalization is $290.63 million. The stock’s 50 day moving average is $1.84 and its 200 day moving average is $2.14.

Curis (NASDAQ:CRIS) last issued its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.01). Curis had a negative net margin of 836.18% and a negative return on equity of 236.43%. The business had revenue of $2.10 million for the quarter, compared to analysts’ expectations of $2.08 million. During the same period last year, the business earned ($0.09) earnings per share. The company’s revenue was up 23.5% on a year-over-year basis. Equities analysts expect that Curis will post ($0.40) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Curis (CRIS) Receives Media Sentiment Rating of 0.14” was first reported by Stock Observer and is the sole property of of Stock Observer. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at

Curis Company Profile

Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.

Insider Buying and Selling by Quarter for Curis (NASDAQ:CRIS)

Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with's FREE daily email newsletter.

Leave a Reply